ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda to sell OTC drug unit to Blackstone for $2.3bn

Japanese pharmaceutical maker in bid to reduce debt inflated by Shire purchase

Takeda Pharmaceutical will sell wholly owned subsidiary Takeda Consumer Healthcare Company, which is involved in Alinamin and other medicine line.

TOKYO -- Japan's Takeda Pharmaceutical has decided to sell its nonprescription drugs business, including vitamin drug Alinamin, to major U.S. private equity firm Blackstone Group for about 250 billion yen ($2.37 billion)

The company intends to reduce debt swollen by Takeda's acquisition of Shire, the U.K. biotech company, and concentrate its management resources on developing prescription drugs, especially cancer treatments.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more